RMD — ResMed Inc. stock price, charts and financials

QT53ResMed Inc.

ResMed Inc. (NYSE: RMD) is a Healthcare company in the Medical - Instruments & Supplies industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
224.99
-3.43-1.50%
RMDQT53ResMed Inc.·NYSE
224.99-1.50%
Analyst
Down 1.5% — RBC Capital upgraded to Outperform, price target $262.
High confidence
TA
Loading chart...
Signal & projected range
Analyst upgradeHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
Snapshot
IndexS&P 500P/E21.63EPS (ttm)10.40Insider Own0.95%Shs Outstand145.06MPerf Week3.08%
Market Cap32.64BForward P/E16.91EPS next Y13.31Insider Trans-3.04%Shs Float144.16MPerf Month-2.45%
Enterprise Value31.96BPEG2.39EPS next Q2.69Inst Own-Short Float9.07%Perf Quarter19.28%
Income1.52BP/S5.77EPS this Y16.30%Inst Trans-Short Ratio8.67Perf Half Y-1.06%
Sales5.65BP/B4.96EPS next Y10.01%ROA16.99%Short Interest13.07MPerf YTD-6.59%
Book/sh45.40P/C22.22EPS next 5Y9.05%ROE23.88%52W High284.87 -21.02%Perf Year-17.19%
Cash/sh10.13P/FCF10.96EPS past 3/5Y19.53% 26.27%ROIC19.11%52W Low180.27 24.81%Perf 3Y53.74%
Dividend Est.2.64 (1.17%)EV/EBITDA14.89Sales past 3/5Y10.21% 12.07%Gross Margin61.16%Volatility2.44% 2.49%Perf 5Y-23.88%
Dividend TTM2.46 (1.09%)EV/Sales5.65EPS Y/Y TTM9.36%Oper. Margin33.48%ATR (14)6.35Perf 10Y235.51%
Dividend Ex-DateAug 20, 2026Quick Ratio2.42Sales Y/Y TTM9.87%Profit Margin26.94%RSI (14)50.00Recom2.74
Dividend Gr. 3/5Y9.53% 7.70%Current Ratio3.10EPS Q/Q24.47%SMA20-1.86%Beta0.74Target Price242.70
Payout40.19%Debt/Eq0.12Sales Q/Q8.61%SMA503.01%Rel Volume2.59Prev Close228.42
Employees11,370LT Debt/Eq0.08EarningsOct 29SMA200-0.97%Avg Volume1.47MPrice224.99
IPO DateJun 02, 1995Option/ShortYes / YesEPS/Sales Surpr.1.98% 0.16%Net Debt/EBITDA-0.30Volume3,818,337Change-1.50%
Analyst Ratings
DateActionAnalystRatingTarget
Sep-15-26UpgradeRBC CapitalSector PerformOutperform$234$262
Aug-31-26ReiteratedKeybancOverweight$255$267
Aug-19-26InitiatedRothschild & Co RedburnNeutral$230
Aug-07-26ReiteratedRobert W. Baird$217$213
Aug-07-26ReiteratedKeybancOverweight$266$255
Jul-21-26ReiteratedUBSBuy$345$300
Jul-16-26ReiteratedRBC CapitalOutperform$276$234
Jul-15-26ReiteratedMizuhoOutperform$265$220
Jul-13-26DowngradeCitigroupBuyNeutral
Jul-10-26ReiteratedJefferiesHold$240$225
Latest News· Times ET
Sep-17-26
Sep-15-26
Sep-14-26
Sep-10-26
Sep-08-26
Sep-07-26
Sep-03-26
Sep-01-26
Aug-31-26
Aug-30-26
Company

ResMed Inc. is a leading global medical technology enterprise engaged in the creation, production, distribution, and marketing of healthcare devices and connected digital solutions. The company operates through two primary segments: Sleep and Respiratory Care, and Software as a Service. Its extensive product range addresses a variety of respiratory disorders, encompassing advanced medical and consumer technologies, ventilation devices, diagnostic equipment, mask systems for both clinical and personal use, headgear, and related accessories, alongside dental devices. ResMed also provides sophisticated cloud-based informatics to enhance patient management and operational efficiency. Notable software offerings in its respiratory portfolio include AirView, for remote device monitoring and setting adjustments; myAir, a personalized application designed to support sleep apnea patients with education and troubleshooting for better engagement and adherence; and U-Sleep, a compliance tracking platform for home medical equipment providers. Complementing these are connectivity modules and Propeller solutions. Furthermore, ResMed offers a robust suite of out-of-hospital software. This includes Brightree, a business management platform for various home care service providers (e.g., HME, pharmacy, infusion, orthotics, prosthetics); MatrixCare, providing care management for senior living, skilled nursing, and hospice organizations; and HEALTHCAREfirst, which supplies electronic health records, billing, coding services, and analytics for home health and hospice agencies. ResMed distributes its offerings primarily to sleep clinics, home healthcare dealers, and hospitals via a global network of distributors and a direct sales force, serving approximately 140 countries. Founded in 1989, the company's headquarters are located in San Diego, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
FY 2026
6/30/2026
FY 2025
6/30/2025
FY 2024
6/30/2024
FY 2023
6/30/2023
FY 2022
6/30/2022
FY 2021
6/30/2021
FY 2020
6/30/2020
FY 2019
6/30/2019
Total Revenue5,6545,6535,146
Cost of Goods Sold Incl. D&A2,1952,1962,091
Gross Profit3,4583,4583,055
Selling, General and Administrative Excl. Other817817991
Research and Development378378331
Other Operating Expense37037048
Operating Income1,8941,8931,685
Interest Expense292913
Unusual Expense
Non-Operating Income (Expense)56565
Net Income Before Taxes1,9191,9191,678
Income Taxes397396277
Consolidated Net Income1,5241,5231,401
Net Income From Continuing Operations1,5241,5231,401
Net Income1,5241,5231,401
EPS (Recurring)10.4410.449.55
EPS (Basic, Before Extraordinaries)10.4410.449.55
EPS (Diluted)10.4010.409.51
EBITDA2,1462,1461,913
Other After Tax Adjustments
Stock Option Compensation Expense
Price To Earnings Ratio21.6318.7427.13
Price To Sales Ratio5.775.007.37
Gross Margin61.1661.1759.37
Operating Margin33.5033.4932.74
Net Margin26.9526.9427.23
Shares Outstanding145145147
Market Capitalization32,62428,25837,926
Operating Lease Expense
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$310.37$274.32$238.28$202.23$166.18 Close Price0.00M0.97M1.95M2.92M3.89MUSD Trades VolumeSepOctNovDec2026FebMarAprMayJunJulAugSep
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Farrell Michael J.Chairman and CEOSep 08 '26Sale222.444,9911,110,191466,256Sep 10
Farrell Michael J.Chairman and CEOSep 08 '26Option Exercise146.344,991730,383471,247Sep 10
FARRELL PETER CDirectorSep 02 '26Sale234.73970227,68851,803Sep 04
Farrell Michael J.Chairman and CEOAug 07 '26Option Exercise146.344,991730,383471,247Aug 11
Farrell Michael J.Chairman and CEOAug 07 '26Sale205.694,9911,026,596466,256Aug 11
FARRELL PETER CDirectorAug 05 '26Sale225.008,0001,800,00052,773Aug 06
Farrell Michael J.Chairman and CEOJul 07 '26Option Exercise146.344,991730,383471,214Jul 09
Farrell Michael J.Chairman and CEOJul 07 '26Sale218.554,9911,090,771466,223Jul 09
Farrell Michael J.Chairman and CEOJun 08 '26Option Exercise146.344,991730,383471,214Jun 09
Farrell Michael J.Chairman and CEOJun 08 '26Sale193.964,991968,064466,256Jun 09
Farrell Michael J.Chairman and CEOMay 07 '26Option Exercise146.344,991730,383471,214May 11
Farrell Michael J.Chairman and CEOMay 07 '26Sale207.824,9911,037,233466,223May 11
Farrell Michael J.Chairman and CEOApr 07 '26Option Exercise146.344,991730,383471,214Apr 09
Farrell Michael J.Chairman and CEOApr 07 '26Sale225.504,9911,125,486466,223Apr 09
Sandercock BrettChief Financial OfficerApr 01 '26Sale224.311,000224,31083,495Apr 03
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.